Matthew W D Perry
Matthew W D Perry
Medicinal Chemistry, RIA iMed, AstraZeneca
Verified email at
Cited by
Cited by
Monocarboxylate transporter MCT1 is a target for immunosuppression
CM Murray, R Hutchinson, JR Bantick, GP Belfield, AD Benjamin, ...
Nature chemical biology 1 (7), 371-376, 2005
PI3K inhibitors are finally coming of age
B Vanhaesebroeck, MWD Perry, JR Brown, F André, K Okkenhaug
Nature Reviews Drug Discovery 20 (10), 741-769, 2021
Designing novel building blocks is an overlooked strategy to improve compound quality
FW Goldberg, JG Kettle, T Kogej, MWD Perry, NP Tomkinson
Drug Discovery Today 20 (1), 11-17, 2015
Structural and conformational determinants of macrocycle cell permeability
B Over, P Matsson, C Tyrchan, P Artursson, BC Doak, MA Foley, ...
Nature Chemical Biology 12 (12), 1065-1074, 2016
Stabilization of protein-protein interactions in drug discovery
SA Andrei, E Sijbesma, M Hann, J Davis, G O’Mahony, MWD Perry, ...
Expert Opinion on Drug Discovery 12 (9), 925-940, 2017
Asynchronously calibrated quantitative bone densitometry
JK Brown, W Timm, G Bodeen, A Chason, M Perry, F Vernacchia, ...
Journal of Clinical Densitometry 20 (2), 216-225, 2017
J Bantick, M Cooper, P Thorne, M Perry
US Patent 6,342,601, 2002
Impact of stereospecific intramolecular hydrogen bonding on cell permeability and physicochemical properties
B Over, P McCarren, P Artursson, M Foley, F Giordanetto, G Grönberg, ...
Journal of medicinal chemistry 57 (6), 2746-2754, 2014
Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds
SD Guile, JR Bantick, DR Cheshire, ME Cooper, AM Davis, DK Donald, ...
Bioorganic & medicinal chemistry letters 16 (8), 2260-2265, 2006
Evolution of PI3Kγ and δ inhibitors for inflammatory and autoimmune diseases
MWD Perry, R Abdulai, M Mogemark, J Petersen, MJ Thomas, B Valastro, ...
Journal of Medicinal Chemistry 62 (10), 4783-4814, 2018
Synthetic FKBP12 ligands. Design and synthesis of pyranose replacements.
TN Birkenshaw, MV Caffrey, DE Cladingboel, ME Cooper, DK Donald, ...
Bioorganic & Medicinal Chemistry Letters 4 (21), 2501-2506, 1994
Azo anions in systhesis. pt 1. t-butylhydrazones as acyl-anion equivalents
JE Baldwin, RM Adlington, JC Bottaro, JN Kolhe, MWD Perry, AU Jain
Tetrahedron 42 (15), 4223-4234, 1986
14-3-3 modulation of the inflammatory response
CC Munier, C Ottmann, MWD Perry
Pharmacological Research 163, 105236, 2021
Applications of the thermal ene reaction of aldehyde t-butyl-and phenyl-hydrazones
JE Baldwin, RM Adlington, AU Jain, JN Kolhe, MWD Perry
Tetrahedron 42 (15), 4247-4252, 1986
Novel piperidine derivatives for use in the treatment of chemokine medicated disease states
C Luckhurst, M Perry, B Springthorpe
US Patent App. 10/528,477, 2006
A class of highly selective inhibitors bind to an active state of PI3Kγ
G Gangadhara, G Dahl, T Bohnacker, R Rae, J Gunnarsson, S Blaho, ...
Nature chemical biology 15 (4), 348-357, 2019
D Cheshire, A Cooke, M Cooper, D Donald, M Furber, M Perry, P Thorne
US Patent 6,180,635, 2001
Design, synthesis, and biological evaluation of MEK PROTACs
S Vollmer, D Cunoosamy, H Lv, H Feng, X Li, Z Nan, W Yang, MWD Perry
Journal of Medicinal Chemistry 63 (1), 157-162, 2019
A Practical Method for Targeted Library Design Balancing Lead‐like Properties with Diversity
MJ Stocks, GRH Wilden, G Pairaudeau, MWD Perry, J Steele, ...
ChemMedChem: Chemistry Enabling Drug Discovery 4 (5), 800-808, 2009
Stereocontrol during the alkylation of enolates attached to. pi.-allyl-Mo (CO) 2Cp systems
AJ Pearson, S Mallik, R Mortezaei, MWD Perry, RJ Shively Jr, WJ Youngs
Journal of the American Chemical Society 112 (22), 8034-8042, 1990
The system can't perform the operation now. Try again later.
Articles 1–20